Irinophore C™, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model

Journal of Controlled Release

Volumn 158, Issue 1, 2012, Pages 34-43

  Verreault, M ^a   Strutt, D ^a   Masin, D ^a   Anantha, M ^a   Waterhouse, D ^a   Yapp, D T ^a,b   Bally, M B ^a,b,c  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Center for Drug Research and Development   (Canada)

Author keywords

Cancer; Drug delivery; Glioblastoma; Irinotecan; Liposomes; Tumor associated vasculature

Indexed keywords

AFTER-TREATMENT; BRAIN TISSUE; CANCER; GLIOBLASTOMAS; IMMUNOSTAINING; IRINOTECAN; MAXIMUM TOLERATED DOSE; NANO PARTICULATES; ORTHOTOPIC; SURVIVAL TIME; THERAPEUTIC EFFICACY; THERAPEUTIC POTENTIALS; VASCULATURE;

CELL PROLIFERATION; DISEASES; DRUG DELIVERY; LIPOSOMES; MAMMALS; PHOSPHOLIPIDS;

TUMORS;

7 ETHYL 10 HYDROXYCAMPTOTHECIN; IRINOPHORE C TM; IRINOTECAN; KI 67 ANTIGEN; LACTONE; NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BRAIN; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; DRUG USE; FEMALE; GLIOBLASTOMA; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; TISSUE LEVEL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAIN; BRAIN NEOPLASMS; CAMPTOTHECIN; CELL LINE, TUMOR; FEMALE; GLIOBLASTOMA; HUMANS; LIPOSOMES; MICE; NANOPARTICLES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84857910834     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2011.09.095     Document Type: Article

References (128)

1. R. Stupp, M.E. Hegi, W.P. Mason, M.J. van den Bent, M.J. Taphoorn, R.C. Janzer, S.K. Ludwin, A. Allgeier, B. Fisher, K. Belanger, P. Hau, A.A. Brandes, J. Gijtenbeek, C. Marosi, C.J. Vecht, K. Mokhtari, P. Wesseling, S. Villa, E. Eisenhauer, T. Gorlia, M. Weller, D. Lacombe, J.G. Cairncross, and R.O. Mirimanoff Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol. 10 2009 459 466
2. R. Stupp, W.P. Mason, M.J. van den Bent, M. Weller, B. Fisher, M.J. Taphoorn, K. Belanger, A.A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R.C. Janzer, S.K. Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J.G. Cairncross, E. Eisenhauer, and R.O. Mirimanoff Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N. Engl. J. Med. 352 2005 987 996 (Pubitemid 40349501)
3. H.S. Friedman, M.D. Prados, P.Y. Wen, T. Mikkelsen, D. Schiff, L.E. Abrey, W.K. Yung, N. Paleologos, M.K. Nicholas, R. Jensen, J. Vredenburgh, J. Huang, M. Zheng, and T. Cloughesy Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J. Clin. Oncol. 27 2009 4733 4740
4. T. Cloughesy FDA accelerated approval benefits glioblastoma Lancet Oncol. 11 2010 1120
5. NCCN, National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology Accessed in February 2011 Anaplastic Glioma/Glioblastoma 2011 Available from www.nccn.org
6. C.D. Turner, S. Gururangan, J. Eastwood, K. Bottom, M. Watral, R. Beason, R.E. McLendon, A.H. Friedman, S. Tourt-Uhlig, L.L. Miller, and H.S. Friedman Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience Neuro Oncol. 4 2002 102 108 (Pubitemid 34285064)
7. J.J. Vredenburgh, A. Desjardins, D.A. Reardon, and H.S. Friedman Experience with irinotecan for the treatment of malignant glioma Neuro Oncol. 11 2009 80 91
8. A.A. Brandes, A. Tosoni, U. Basso, M. Reni, F. Valduga, S. Monfardini, P. Amista, L. Nicolardi, G. Sotti, and M. Ermani Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO) J. Clin. Oncol. 22 2004 4779 4786
9. J.A. Quinn, S.X. Jiang, D.A. Reardon, A. Desjardins, J.J. Vredenburgh, A.H. Friedman, J.H. Sampson, R.E. McLendon, J.E. Herndon II, and H.S. Friedman Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy J. Neurooncol. 95 2009 393 400
10. P. Tobin, L. Rivory, and S. Clarke Inhibition of acetylcholinesterase in patients receiving irinotecan (camptothecin-11) Clin. Pharmacol. Ther. 76 2004 505 506 author reply 507-508
11. E. Ramsay, J. Alnajim, M. Anantha, J. Zastre, H. Yan, M. Webb, D. Waterhouse, and M. Bally A novel liposomal irinotecan formulation with significant anti-tumour activity: use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention Eur. J. Pharm. Biopharm. 68 2008 607 617 (Pubitemid 351318211)
12. E.C. Ramsay, M. Anantha, J. Zastre, M. Meijs, J. Zonderhuis, D. Strutt, M.S. Webb, D. Waterhouse, and M.B. Bally Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors Clin. Cancer Res. 14 2008 1208 1217 (Pubitemid 351302570)
13. M.J. Hatfield, L. Tsurkan, M. Garrett, T.M. Shaver, J.L. Hyatt, C.C. Edwards, L.D. Hicks, and P.M. Potter Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11 Biochem. Pharmacol. 81 2011 24 31
14. S. Ghosh Cholesteryl ester hydrolase in human monocyte/macrophage: cloning, sequencing, and expression of full-length cDNA Physiol. Genomics 2 2000 1 8
15. S. Wera, J.C. Bergsma, and J.M. Thevelein Phosphoinositides in yeast: genetically tractable signalling FEMS Yeast Res. 1 2001 9 13 (Pubitemid 34442289)
16. W. Wang, A. Ghandi, L. Liebes, S.G. Louie, F.M. Hofman, A.H. Schonthal, and T.C. Chen Effective conversion of irinotecan to SN-38 after intratumoral drug delivery to an intracranial murine glioma model in vivo. Laboratory investigation J. Neurosurg. 114 2011 689 694
17. F. Lavelle, M.C. Bissery, S. Andre, F. Roquet, and J.F. Riou Preclinical evaluation of CPT-11 and its active metabolite SN-38 Semin. Oncol. 23 1996 11 20 (Pubitemid 26117267)
18. Y. Sadzuka, S. Hirotsu, and S. Hirota Effective irinotecan (CPT-11)-containing liposomes: intraliposomal conversion to the active metabolite SN-38 Jpn. J. Cancer Res. 90 1999 226 232 (Pubitemid 29112324)
19. D.C. Drummond, C.O. Noble, Z. Guo, K. Hong, J.W. Park, and D.B. Kirpotin Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy Cancer Res. 66 2006 3271 3277
20. K. Riviere, H.M. Kieler-Ferguson, K. Jerger, and F.C. Szoka Jr. Anti-tumor activity of liposome encapsulated fluoroorotic acid as a single agent and in combination with liposome irinotecan J. Control. Release 153 2011 288 296
21. C. Li, J. Cui, C. Wang, Y. Li, L. Zhang, X. Xiu, N. Wei, and P. Wang Novel sulfobutyl ether cyclodextrin gradient leads to highly active liposomal irinotecan formulation J. Pharm. Pharmacol. 63 2011 765 773
22. Y. Hattori, L. Shi, W. Ding, K. Koga, K. Kawano, M. Hakoshima, and Y. Maitani Novel irinotecan-loaded liposome using phytic acid with high therapeutic efficacy for colon tumors J. Control. Release 136 2009 30 37
23. P. Shende, and R. Gaud Formulation and comparative characterization of chitosan, gelatin, and chitosan-gelatin-coated liposomes of CPT-11-HCl Drug Dev. Ind. Pharm. 35 2009 612 618
24. S. Khan, A. Ahmad, W. Guo, Y.F. Wang, A. Abu-Qare, and I. Ahmad A simple and sensitive LC/MS/MS assay for 7-ethyl-10-hydroxycamptothecin (SN-38) in mouse plasma and tissues: application to pharmacokinetic study of liposome entrapped SN-38 (LE-SN38) J. Pharm. Biomed. Anal. 37 2005 135 142 (Pubitemid 40138726)
25. F. Atyabi, A. Farkhondehfai, F. Esmaeili, and R. Dinarvand Preparation of pegylated nano-liposomal formulation containing SN-38: In vitro characterization and in vivo biodistribution in mice Acta Pharm. 59 2009 133 144
26. P. Sapra, H. Zhao, M. Mehlig, J. Malaby, P. Kraft, C. Longley, L.M. Greenberger, and I.D. Horak Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model Clin. Cancer Res. 14 2008 1888 1896 (Pubitemid 351469476)
27. L.D. Mayer, M.J. Hope, and P.R. Cullis Vesicles of variable sizes produced by a rapid extrusion procedure Biochim. Biophys. Acta 858 1986 161 168
28. M.B. Bally, L.D. Mayer, M.J. Hope, and R. Nayar G. Gregoriadis, Chapter 3: Pharmacodynamics of liposomal drug carriers: methodological considerations 2nd edition Liposome Technology Volume III 1993 CRC Press Inc.
29. S.M. Blaney, C. Takimoto, D.J. Murry, N. Kuttesch, C. McCully, D.E. Cole, K. Godwin, and F.M. Balis Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates Cancer Chemother. Pharmacol. 41 1998 464 468 (Pubitemid 28140710)
30. H.H. Engerhard, D.G. Groothuis, and S.W. Coons Chapter 11: The Blood-brain barrier: Structure, Function, and Response to Neoplasia & Chapter 20: Anatomy and Growth Patterns of Diffuse Gliomas Gliomas 1 1999 115 121
31. H. Maeda, G.Y. Bharate, and J. Daruwalla Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect Eur. J. Pharm. Biopharm. 71 2009 409 419
32. W.C. Zamboni, P.J. Houghton, J. Thompson, P.J. Cheshire, S.K. Hanna, L.B. Richmond, X. Lou, and C.F. Stewart Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts Clin. Cancer Res. 4 1998 455 462 (Pubitemid 28122763)
33. M. Verreault, D. Strutt, D. Masin, M. Anantha, A. Yung, P. Kozlowski, D. Waterhouse, M.B. Bally, and D.T. Yapp Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore CTM), doxorubicin (Caelyx®) or vincristine BMC Cancer Apr. 8 2011 124 142
34. J.H. Baker, J. Lam, A.H. Kyle, J. Sy, T. Oliver, S.J. Co, W.H. Dragowska, E. Ramsay, M. Anantha, T.J. Ruth, M.J. Adam, A. Yung, P. Kozlowski, A.I. Minchinton, S.S. Ng, M.B. Bally, and D.T. Yapp Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin Clin. Cancer Res. 14 2008 7260 7271
35. R.K. Jain Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 307 2005 58 62 (Pubitemid 40093472)
36. J. Ma, S. Li, K. Reed, P. Guo, and J.M. Gallo Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models J. Pharmacol. Exp. Ther. 305 2003 833 839 (Pubitemid 36617958)
37. D. Fukumura, and R.K. Jain Imaging angiogenesis and the microenvironment APMIS 116 2008 695 715
38. A.G. Sorensen, T.T. Batchelor, W.T. Zhang, P.J. Chen, P. Yeo, M. Wang, D. Jennings, P.Y. Wen, J. Lahdenranta, M. Ancukiewicz, E. di Tomaso, D.G. Duda, and R.K. Jain A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients Cancer Res. 69 2009 5296 5300
39. A.W. Le Serve, and K. Hellmann Vascular changes in tumours after treatment with ICRF 159 Br. J. Pharmacol. 43 1971 457P 458P
40. F. Baffert, T. Le, B. Sennino, G. Thurston, C.J. Kuo, D. Hu-Lowe, and D.M. McDonald Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling Am. J. Physiol. Heart Circ. Physiol. 290 2006 H547 H559
41. R.K. Jain Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy Nat. Med. 7 2001 987 989 (Pubitemid 32937367)
42. P. Vajkoczy, and M.D. Menger Vascular microenvironment in gliomas Cancer Treat. Res. 117 2004 249 262
43. B.R. Deane, and P.L. Lantos The vasculature of experimental brain tumours. Part 1. A sequential light and electron microscope study of angiogenesis J. Neurol. Sci. 49 1981 55 66 (Pubitemid 11217486)
44. R.G. Blasberg, T. Kobayashi, M. Horowitz, J.M. Rice, D. Groothuis, P. Molnar, and J.D. Fenstermacher Regional blood flow in ethylnitrosourea-induced brain tumors Ann. Neurol. 14 1983 189 201 (Pubitemid 13030274)
45. D.R. Groothuis, J.F. Pasternak, J.M. Fischer, R.G. Blasberg, D.D. Bigner, and N.A. Vick Regional measurements of blood flow in experimental RG-2 rat gliomas Cancer Res. 43 1983 3362 3367 (Pubitemid 13061598)
46. F. Yuan, H.A. Salehi, Y. Boucher, U.S. Vasthare, R.F. Tuma, and R.K. Jain Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows Cancer Res. 54 1994 4564 4568 (Pubitemid 24276471)
47. P. Vajkoczy, and M.D. Menger Vascular microenvironment in gliomas J. Neurooncol. 50 2000 99 108 (Pubitemid 32166294)
48. J.W. Baish, Y. Gazit, D.A. Berk, M. Nozue, L.T. Baxter, and R.K. Jain Role of tumor vascular architecture in nutrient and drug delivery: an invasion percolation-based network model Microvasc. Res. 51 1996 327 346 (Pubitemid 26162001)
49. W.S. Kamoun, C.D. Ley, C.T. Farrar, A.M. Duyverman, J. Lahdenranta, D.A. Lacorre, T.T. Batchelor, E. di Tomaso, D.G. Duda, L.L. Munn, D. Fukumura, A.G. Sorensen, and R.K. Jain Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice J. Clin. Oncol. 27 2009 2542 2552
50. F. Winkler, S.V. Kozin, R.T. Tong, S.S. Chae, M.F. Booth, I. Garkavtsev, L. Xu, D.J. Hicklin, D. Fukumura, E. di Tomaso, L.L. Munn, and R.K. Jain Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases Cancer Cell 6 2004 553 563 (Pubitemid 40017699)
51. Q. Zhou, and J.M. Gallo Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model Neuro Oncol. 11 2009 301 310
52. G. Bocci, A. Falcone, A. Fioravanti, P. Orlandi, A. Di Paolo, G. Fanelli, P. Viacava, A.G. Naccarato, R.S. Kerbel, R. Danesi, M. Del Tacca, and G. Allegrini Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib Br. J. Cancer 98 2008 1619 1629 (Pubitemid 351684682)
53. G. Bergers, and D. Hanahan Modes of resistance to anti-angiogenic therapy Nat. Rev. Cancer 8 2008 592 603
54. H. Sarin, A.S. Kanevsky, H. Wu, K.R. Brimacombe, S.H. Fung, A.A. Sousa, S. Auh, C.M. Wilson, K. Sharma, M.A. Aronova, R.D. Leapman, G.L. Griffiths, and M.D. Hall Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells J. Transl. Med. 6 2008 80
55. T.D. Tailor, G. Hanna, P.S. Yarmolenko, M.R. Dreher, A.S. Betof, A.B. Nixon, I. Spasojevic, and M.W. Dewhirst Effect of pazopanib on tumor microenvironment and liposome delivery Mol. Cancer Ther. 9 2010 1798 1808
56. W.A. Banks Characteristics of compounds that cross the blood-brain barrier BMC Neurol. 9 Suppl. 1 2009 S3
57. G. Storm, P.A. Steerenberg, F. Emmen, M. van Borssum Waalkes, and D.J. Crommelin Release of doxorubicin from peritoneal macrophages exposed in vivo to doxorubicin-containing liposomes Biochim. Biophys. Acta 965 1988 136 145
58. R.H. te Poele, and S.P. Joel Schedule-dependent cytotoxicity of SN-38 in p53 wild-type and mutant colon adenocarcinoma cell lines Br. J. Cancer 81 1999 1285 1293
59. A. Wallin, J. Svanvik, B. Holmlund, L. Ferreud, and X.F. Sun Anticancer effect of SN-38 on colon cancer cell lines with different metastatic potential Oncol. Rep. 19 2008 1493 1498
60. H. Kamiyama, S. Takano, K. Tsuboi, and A. Matsumura Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1alpha)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells J. Cancer Res. Clin. Oncol. 131 2005 205 213 (Pubitemid 40238935)
61. G. Allegrini, A. Falcone, A. Fioravanti, M.T. Barletta, P. Orlandi, F. Loupakis, E. Cerri, G. Masi, A. Di Paolo, R.S. Kerbel, R. Danesi, M. Del Tacca, and G. Bocci A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients Br. J. Cancer 98 2008 1312 1319 (Pubitemid 351543577)
62. L.P. Rivory, E. Chatelut, P. Canal, A. Mathieu-Boue, and J. Robert Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients Cancer Res. 54 1994 6330 6333
63. T.G. Burke, and Z. Mi The structural basis of camptothecin interactions with human serum albumin: impact on drug stability J. Med. Chem. 37 1994 40 46 (Pubitemid 24058811)
64. Y. Sadzuka Effective prodrug liposome and conversion to active metabolite Curr. Drug Metab. 1 2000 31 48
65. R. Stupp, M.E. Hegi, W.P. Mason, M.J. van den Bent, M.J. Taphoorn, R.C. Janzer, S.K. Ludwin, A. Allgeier, B. Fisher, K. Belanger, P. Hau, A.A. Brandes, J. Gijtenbeek, C. Marosi, C.J. Vecht, K. Mokhtari, P. Wesseling, S. Villa, E. Eisenhauer, T. Gorlia, M. Weller, D. Lacombe, J.G. Cairncross, and R.O. Mirimanoff Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol. 10 2009 459 466
66. R. Stupp, W.P. Mason, M.J. van den Bent, M. Weller, B. Fisher, M.J. Taphoorn, K. Belanger, A.A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R.C. Janzer, S.K. Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J.G. Cairncross, E. Eisenhauer, and R.O. Mirimanoff Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N. Engl. J. Med. 352 2005 987 996 (Pubitemid 40349501)
67. H.S. Friedman, M.D. Prados, P.Y. Wen, T. Mikkelsen, D. Schiff, L.E. Abrey, W.K. Yung, N. Paleologos, M.K. Nicholas, R. Jensen, J. Vredenburgh, J. Huang, M. Zheng, and T. Cloughesy Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J. Clin. Oncol. 27 2009 4733 4740
68. T. Cloughesy FDA accelerated approval benefits glioblastoma Lancet Oncol. 11 2010 1120
69. NCCN, National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology Accessed in February 2011 Anaplastic Glioma/Glioblastoma 2011 Available from www.nccn.org
70. C.D. Turner, S. Gururangan, J. Eastwood, K. Bottom, M. Watral, R. Beason, R.E. McLendon, A.H. Friedman, S. Tourt-Uhlig, L.L. Miller, and H.S. Friedman Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience Neuro Oncol. 4 2002 102 108 (Pubitemid 34285064)
71. J.J. Vredenburgh, A. Desjardins, D.A. Reardon, and H.S. Friedman Experience with irinotecan for the treatment of malignant glioma Neuro Oncol. 11 2009 80 91
72. A.A. Brandes, A. Tosoni, U. Basso, M. Reni, F. Valduga, S. Monfardini, P. Amista, L. Nicolardi, G. Sotti, and M. Ermani Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO) J. Clin. Oncol. 22 2004 4779 4786
73. J.A. Quinn, S.X. Jiang, D.A. Reardon, A. Desjardins, J.J. Vredenburgh, A.H. Friedman, J.H. Sampson, R.E. McLendon, J.E. Herndon II, and H.S. Friedman Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy J. Neurooncol. 95 2009 393 400
74. P. Tobin, L. Rivory, and S. Clarke Inhibition of acetylcholinesterase in patients receiving irinotecan (camptothecin-11) Clin. Pharmacol. Ther. 76 2004 505 506 author reply 507-508
75. E. Ramsay, J. Alnajim, M. Anantha, J. Zastre, H. Yan, M. Webb, D. Waterhouse, and M. Bally A novel liposomal irinotecan formulation with significant anti-tumour activity: use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention Eur. J. Pharm. Biopharm. 68 2008 607 617 (Pubitemid 351318211)
76. E.C. Ramsay, M. Anantha, J. Zastre, M. Meijs, J. Zonderhuis, D. Strutt, M.S. Webb, D. Waterhouse, and M.B. Bally Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors Clin. Cancer Res. 14 2008 1208 1217 (Pubitemid 351302570)
77. M.J. Hatfield, L. Tsurkan, M. Garrett, T.M. Shaver, J.L. Hyatt, C.C. Edwards, L.D. Hicks, and P.M. Potter Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11 Biochem. Pharmacol. 81 2011 24 31
78. S. Ghosh Cholesteryl ester hydrolase in human monocyte/macrophage: cloning, sequencing, and expression of full-length cDNA Physiol. Genomics 2 2000 1 8
79. S. Wera, J.C. Bergsma, and J.M. Thevelein Phosphoinositides in yeast: genetically tractable signalling FEMS Yeast Res. 1 2001 9 13 (Pubitemid 34442289)
80. W. Wang, A. Ghandi, L. Liebes, S.G. Louie, F.M. Hofman, A.H. Schonthal, and T.C. Chen Effective conversion of irinotecan to SN-38 after intratumoral drug delivery to an intracranial murine glioma model in vivo. Laboratory investigation J. Neurosurg. 114 2011 689 694
81. F. Lavelle, M.C. Bissery, S. Andre, F. Roquet, and J.F. Riou Preclinical evaluation of CPT-11 and its active metabolite SN-38 Semin. Oncol. 23 1996 11 20 (Pubitemid 26117267)
82. Y. Sadzuka, S. Hirotsu, and S. Hirota Effective irinotecan (CPT-11)-containing liposomes: intraliposomal conversion to the active metabolite SN-38 Jpn. J. Cancer Res. 90 1999 226 232 (Pubitemid 29112324)
83. D.C. Drummond, C.O. Noble, Z. Guo, K. Hong, J.W. Park, and D.B. Kirpotin Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy Cancer Res. 66 2006 3271 3277
84. K. Riviere, H.M. Kieler-Ferguson, K. Jerger, and F.C. Szoka Jr. Anti-tumor activity of liposome encapsulated fluoroorotic acid as a single agent and in combination with liposome irinotecan J. Control. Release 153 2011 288 296
85. C. Li, J. Cui, C. Wang, Y. Li, L. Zhang, X. Xiu, N. Wei, and P. Wang Novel sulfobutyl ether cyclodextrin gradient leads to highly active liposomal irinotecan formulation J. Pharm. Pharmacol. 63 2011 765 773
86. Y. Hattori, L. Shi, W. Ding, K. Koga, K. Kawano, M. Hakoshima, and Y. Maitani Novel irinotecan-loaded liposome using phytic acid with high therapeutic efficacy for colon tumors J. Control. Release 136 2009 30 37
87. P. Shende, and R. Gaud Formulation and comparative characterization of chitosan, gelatin, and chitosan-gelatin-coated liposomes of CPT-11-HCl Drug Dev. Ind. Pharm. 35 2009 612 618
88. S. Khan, A. Ahmad, W. Guo, Y.F. Wang, A. Abu-Qare, and I. Ahmad A simple and sensitive LC/MS/MS assay for 7-ethyl-10-hydroxycamptothecin (SN-38) in mouse plasma and tissues: application to pharmacokinetic study of liposome entrapped SN-38 (LE-SN38) J. Pharm. Biomed. Anal. 37 2005 135 142 (Pubitemid 40138726)
89. F. Atyabi, A. Farkhondehfai, F. Esmaeili, and R. Dinarvand Preparation of pegylated nano-liposomal formulation containing SN-38: In vitro characterization and in vivo biodistribution in mice Acta Pharm. 59 2009 133 144
90. P. Sapra, H. Zhao, M. Mehlig, J. Malaby, P. Kraft, C. Longley, L.M. Greenberger, and I.D. Horak Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model Clin. Cancer Res. 14 2008 1888 1896 (Pubitemid 351469476)
91. L.D. Mayer, M.J. Hope, and P.R. Cullis Vesicles of variable sizes produced by a rapid extrusion procedure Biochim. Biophys. Acta 858 1986 161 168
92. M.B. Bally, L.D. Mayer, M.J. Hope, and R. Nayar G. Gregoriadis, Chapter 3: Pharmacodynamics of liposomal drug carriers: methodological considerations 2nd edition Liposome Technology Volume III 1993 CRC Press Inc.
93. S.M. Blaney, C. Takimoto, D.J. Murry, N. Kuttesch, C. McCully, D.E. Cole, K. Godwin, and F.M. Balis Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates Cancer Chemother. Pharmacol. 41 1998 464 468 (Pubitemid 28140710)
94. H.H. Engerhard, D.G. Groothuis, and S.W. Coons Chapter 11: The Blood-brain barrier: Structure, Function, and Response to Neoplasia & Chapter 20: Anatomy and Growth Patterns of Diffuse Gliomas Gliomas 1 1999 115 121
95. H. Maeda, G.Y. Bharate, and J. Daruwalla Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect Eur. J. Pharm. Biopharm. 71 2009 409 419
96. W.C. Zamboni, P.J. Houghton, J. Thompson, P.J. Cheshire, S.K. Hanna, L.B. Richmond, X. Lou, and C.F. Stewart Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts Clin. Cancer Res. 4 1998 455 462 (Pubitemid 28122763)
97. M. Verreault, D. Strutt, D. Masin, M. Anantha, A. Yung, P. Kozlowski, D. Waterhouse, M.B. Bally, and D.T. Yapp Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore CTM), doxorubicin (Caelyx®) or vincristine BMC Cancer Apr. 8 2011 124 142
98. J.H. Baker, J. Lam, A.H. Kyle, J. Sy, T. Oliver, S.J. Co, W.H. Dragowska, E. Ramsay, M. Anantha, T.J. Ruth, M.J. Adam, A. Yung, P. Kozlowski, A.I. Minchinton, S.S. Ng, M.B. Bally, and D.T. Yapp Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin Clin. Cancer Res. 14 2008 7260 7271
99. R.K. Jain Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 307 2005 58 62 (Pubitemid 40093472)
100. J. Ma, S. Li, K. Reed, P. Guo, and J.M. Gallo Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models J. Pharmacol. Exp. Ther. 305 2003 833 839 (Pubitemid 36617958)
101. D. Fukumura, and R.K. Jain Imaging angiogenesis and the microenvironment APMIS 116 2008 695 715
102. A.G. Sorensen, T.T. Batchelor, W.T. Zhang, P.J. Chen, P. Yeo, M. Wang, D. Jennings, P.Y. Wen, J. Lahdenranta, M. Ancukiewicz, E. di Tomaso, D.G. Duda, and R.K. Jain A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients Cancer Res. 69 2009 5296 5300
103. A.W. Le Serve, and K. Hellmann Vascular changes in tumours after treatment with ICRF 159 Br. J. Pharmacol. 43 1971 457P 458P
104. F. Baffert, T. Le, B. Sennino, G. Thurston, C.J. Kuo, D. Hu-Lowe, and D.M. McDonald Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling Am. J. Physiol. Heart Circ. Physiol. 290 2006 H547 H559
105. R.K. Jain Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy Nat. Med. 7 2001 987 989 (Pubitemid 32937367)
106. P. Vajkoczy, and M.D. Menger Vascular microenvironment in gliomas Cancer Treat. Res. 117 2004 249 262
107. B.R. Deane, and P.L. Lantos The vasculature of experimental brain tumours. Part 1. A sequential light and electron microscope study of angiogenesis J. Neurol. Sci. 49 1981 55 66 (Pubitemid 11217486)
108. R.G. Blasberg, T. Kobayashi, M. Horowitz, J.M. Rice, D. Groothuis, P. Molnar, and J.D. Fenstermacher Regional blood flow in ethylnitrosourea-induced brain tumors Ann. Neurol. 14 1983 189 201 (Pubitemid 13030274)
109. D.R. Groothuis, J.F. Pasternak, J.M. Fischer, R.G. Blasberg, D.D. Bigner, and N.A. Vick Regional measurements of blood flow in experimental RG-2 rat gliomas Cancer Res. 43 1983 3362 3367 (Pubitemid 13061598)
110. F. Yuan, H.A. Salehi, Y. Boucher, U.S. Vasthare, R.F. Tuma, and R.K. Jain Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows Cancer Res. 54 1994 4564 4568 (Pubitemid 24276471)
111. P. Vajkoczy, and M.D. Menger Vascular microenvironment in gliomas J. Neurooncol. 50 2000 99 108 (Pubitemid 32166294)
112. J.W. Baish, Y. Gazit, D.A. Berk, M. Nozue, L.T. Baxter, and R.K. Jain Role of tumor vascular architecture in nutrient and drug delivery: an invasion percolation-based network model Microvasc. Res. 51 1996 327 346 (Pubitemid 26162001)
113. W.S. Kamoun, C.D. Ley, C.T. Farrar, A.M. Duyverman, J. Lahdenranta, D.A. Lacorre, T.T. Batchelor, E. di Tomaso, D.G. Duda, L.L. Munn, D. Fukumura, A.G. Sorensen, and R.K. Jain Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice J. Clin. Oncol. 27 2009 2542 2552
114. F. Winkler, S.V. Kozin, R.T. Tong, S.S. Chae, M.F. Booth, I. Garkavtsev, L. Xu, D.J. Hicklin, D. Fukumura, E. di Tomaso, L.L. Munn, and R.K. Jain Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases Cancer Cell 6 2004 553 563 (Pubitemid 40017699)
115. Q. Zhou, and J.M. Gallo Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model Neuro Oncol. 11 2009 301 310
116. G. Bocci, A. Falcone, A. Fioravanti, P. Orlandi, A. Di Paolo, G. Fanelli, P. Viacava, A.G. Naccarato, R.S. Kerbel, R. Danesi, M. Del Tacca, and G. Allegrini Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib Br. J. Cancer 98 2008 1619 1629 (Pubitemid 351684682)
117. G. Bergers, and D. Hanahan Modes of resistance to anti-angiogenic therapy Nat. Rev. Cancer 8 2008 592 603
118. H. Sarin, A.S. Kanevsky, H. Wu, K.R. Brimacombe, S.H. Fung, A.A. Sousa, S. Auh, C.M. Wilson, K. Sharma, M.A. Aronova, R.D. Leapman, G.L. Griffiths, and M.D. Hall Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells J. Transl. Med. 6 2008 80
119. T.D. Tailor, G. Hanna, P.S. Yarmolenko, M.R. Dreher, A.S. Betof, A.B. Nixon, I. Spasojevic, and M.W. Dewhirst Effect of pazopanib on tumor microenvironment and liposome delivery Mol. Cancer Ther. 9 2010 1798 1808
120. W.A. Banks Characteristics of compounds that cross the blood-brain barrier BMC Neurol. 9 Suppl. 1 2009 S3
121. G. Storm, P.A. Steerenberg, F. Emmen, M. van Borssum Waalkes, and D.J. Crommelin Release of doxorubicin from peritoneal macrophages exposed in vivo to doxorubicin-containing liposomes Biochim. Biophys. Acta 965 1988 136 145
122. R.H. te Poele, and S.P. Joel Schedule-dependent cytotoxicity of SN-38 in p53 wild-type and mutant colon adenocarcinoma cell lines Br. J. Cancer 81 1999 1285 1293
123. A. Wallin, J. Svanvik, B. Holmlund, L. Ferreud, and X.F. Sun Anticancer effect of SN-38 on colon cancer cell lines with different metastatic potential Oncol. Rep. 19 2008 1493 1498
124. H. Kamiyama, S. Takano, K. Tsuboi, and A. Matsumura Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1alpha)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells J. Cancer Res. Clin. Oncol. 131 2005 205 213 (Pubitemid 40238935)
125. G. Allegrini, A. Falcone, A. Fioravanti, M.T. Barletta, P. Orlandi, F. Loupakis, E. Cerri, G. Masi, A. Di Paolo, R.S. Kerbel, R. Danesi, M. Del Tacca, and G. Bocci A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients Br. J. Cancer 98 2008 1312 1319 (Pubitemid 351543577)
126. L.P. Rivory, E. Chatelut, P. Canal, A. Mathieu-Boue, and J. Robert Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients Cancer Res. 54 1994 6330 6333
127. T.G. Burke, and Z. Mi The structural basis of camptothecin interactions with human serum albumin: impact on drug stability J. Med. Chem. 37 1994 40 46 (Pubitemid 24058811)
128. Y. Sadzuka Effective prodrug liposome and conversion to active metabolite Curr. Drug Metab. 1 2000 31 48